Pancreatic NET (PNET)

Insulinoma

• upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism

PRRT/RLT Trials

• Alpha PRRT with Pb-212 (all NET)

• Alpha PRRT with Ac-225 (GEP-NETs only)

• Alpha PRRT with Pb-212 VMT

• Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs

• Lu-177 DOTATATE + M3814 (Peposertib)  (GEP-NETs)

• Lu-177 DOTATATE + Olaparib  (GEP-NETs)

• Lu-177 DOTATATE + Triapine (GEP-NETs)

• Lu-177 DOTATATE + Cabozantanib (all NET)

• Lu-177 DOTATATE + Sunitinib in PNETs

• COMPOSE (GEP-NETS)

• ComPareNET Lu-177 vs CAPTEM in PNETs

• Lu-177 DOTATATE vs Everolimus in Lung NETs

• NETTER-P: Lutathera in Adolescent Patients

Oral Treatment

• SWOG S2104: Adjuvant CAPTEM for High Risk pNET

• Belzutifan/MK-6482  in PNET + PPGL + VHL

• CDK4/6 Abemaciclib

Other Trials

• Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

• BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors

• IL13Rα2 CAR T Cell Study for Solid Tumor Cancers

• SORENTO™: Subcutaneous Octreotide for GEP-NETs

• Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs)

• SORENTO™: Subcutaneous Octreotide for GEP-NETs

• STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors

• Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs

• Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms